NextBiomedical Submits IPO Prospectus Highlighting Nexpowder: A Novel Endoscopic Hemostatic Powder That Reduces Rebleeding in Non-Variceal Upper GI Bleeding by 74%

May 31, 2025 22:16 CST Updated 22:16

Medtronic

Medical Device Manufacturer

Nextbiomedical Announces Its Innovative Hemostatic Powder Product---NexpowderThe research findings were published in *GUT* (Impact Factor: 23), the most influential journal in the field of gastroenterology worldwide. The study showed that for patients with non-variceal upper gastrointestinal bleeding (NVUGIB), the use of Nexpowder after successful endoscopic hemostasis significantly reduced the risk of rebleeding.

This study is a multicenter randomized controlled trial conducted at three top university hospitals in Korea. A total of 341 patients were enrolled.(Male patients accounted for 72.1%; the average age was 64.8 years). These patientsRandomly assigned to receive Nexpowder treatment or no further treatment (control group).

Specific Research Results：

Rebleeding Rate within 72 Hours: Nexpowder™ Group 2.9% vs Control Group 11.3% (p=0.005)
30-Day Cumulative Rebleeding Rate: 7.0% vs 18.8% (p=0.004)
Ulcer Subgroup (3-day Rebleeding Rate): 3.0% vs 12.0% (p=0.004)
No adverse events related to product application were reported.

Conclusion

The use of Nexpowder after endoscopic hemostasis significantly reduced the early (within 3 days) and late (within 30 days) rebleeding rates in NVUGIB patients, especially in cases of ulcer-related bleeding.

Executive Evaluation

"As the first-in-class innovative drug solution for preventing rebleeding, this multicenter randomized controlled trial with high statistical power has achieved statistically significant results, demonstrating that Nexpowder can deliver clinical benefits surpassing current standard therapies. These findings not only validate the scientific rigor of our research platform but also have the potential to drive a paradigm shift in the treatment of upper gastrointestinal bleeding. We believe this data will accelerate the global promotion of the product and provide a basis for future guideline development."

---Nextbiomedical Chief Technology Officer

Nexpowder

NexpowderIt is a novel powder hemostasis technology under digestive endoscopy, which uses a non-contact, non-thermal, and non-traumatic hemostatic powder sprayed through a catheter. The hemostatic powder, with appropriate powder coating technology, minimizes blockage and enhances visibility and control in the treatment of non-variceal upper gastrointestinal bleeding.

NexpowderByHemostatic Powder, DeliveryHandle and JetCatheter composition, with its powder being the core technology.

Hemostatic PowderYesA hydrophilic biocompatible adhesive material, composed ofComposed of succinic anhydride (ε-poly-(L-lysine)) and oxidized dextran. These two compounds canForms a sticky gel through reversible cross-linking upon contact with water or blood. The cross-linked gel adheres to the bleeding sites in the gastrointestinal tract, and then the gel degrades within 1 to 3 days, helping to prevent bleeding, fluid loss, and contamination of the bleeding site.

NexpowderThisHemostatic Powder and MarketThe difference with other products on the market is that,It reacts not only to blood but also to moisture.It turns into an adhesive, sticking to the bleeding area and promoting healing. This reaction to moisture also means it can be used for other purposes.

NexpowderAndHemosprayExcept for the different hemostatic powder,NexpowderStill upgrading the delivery handle. No longer likeHemospraySimilarly, powder delivery is achieved through carbon dioxide and compressed air technology, with its own unique conveying mechanism, avoidingHemospraySometimes these powders can clog machines, block equipment, or obstruct the doctor's view.

Nexpowder Demonstration

NEXTBIOMEDICAL

NEXTBIOMEDICALIt is an innovative medical device company that focuses on developing innovative therapeutic materials by utilizing advanced drug delivery systems. It specializes in the research, development, and manufacturing of drug-device combination products specifically tailored to address significant unmet clinical needs.